Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 3, 2023
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
Anupam Rama Initiated (SNDX) at Buy and Held Target at $41 on, Jan 3rd, 2023
Anupam Rama of JP Morgan, Initiated "Syndax Pharmaceuticals, Inc." (SNDX) at Buy and Held Target at $41 on, Jan 3rd, 2023.
Anupam has made no other calls on SNDX in the last 4 months.
There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 0 agree with Anupam's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anupam
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $33 on, Monday, December 12th, 2022
- Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $39 on, Monday, December 12th, 2022
